Insight journal - Dealtalk, Pharma

Pharmaceutical trends: Samsung eyes generic biological medicines

Posted on 17 April 2012

Tags: , ,

Samsung, the South Korean conglomerate, plans to launch generic  versions of biological medicines by 2015 at half the current western prices,  as it gears up to challenge US and European pharmaceutical  companies.

Tae-Han Kim, president of Samsung BioLogics, said his company aimed to  complete a manufacturing plant outside Seoul by June, and win international  regulatory approval for the factory by the end of this year.

Read the full article at Financial Times



Read: more on dealtalk  in pharma, biotech, life science partnering deal news, insights and glossary

Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

One Response to “Pharmaceutical trends: Samsung eyes generic biological medicines”

  1. camilo rey says:

    I am interested in this article

Leave a Reply